Alfred Siu, Founder of First Renhui Group: Life Science Technology Empowers High-Quality Human Development

On April 26, 2024, MR. ALFRED SIU (Xiao Yongfeng), Founder and Chairman of First Renhui Group and Founding Council Member of the World Fertility Industry Alliance (WFA), delivered a keynote speech titled “Advancing High-Quality Human Development Through Life Science Technology” at the WFA Brand Summit.

On April 26, 2024, MR. ALFRED SIU (Xiao Yongfeng), Founder and Chairman of First Renhui Group and Founding Council Member of the World Fertility Industry Alliance (WFA), delivered a keynote speech titled “Advancing High-Quality Human Development Through Life Science Technology” at the WFA Brand Summit. Drawing upon his profound professional expertise and extensive industry experience, Mr. Siu thoroughly examined the critical role of life science technology in human development and shared First Renhui Group’s innovative practices and future roadmap in this field.

First Renhui Group—also known as First IVF Group—has rapidly grown since its establishment in 2014 into a leading, full-service life science healthcare group in Asia. The Group has established assisted reproductive medicine centers in Thailand, Cambodia, Kyrgyzstan, and other locations, primarily serving fertility patients from China, Hong Kong, and Southeast Asia. Mr. Siu stated that First Renhui Group’s vision is to become Asia’s “Progyny,” delivering the most advanced and comprehensive life science healthcare services to empower high-quality human development.

In his speech, Mr. Siu detailed First Renhui Group’s service offerings and technological capabilities. The Group provides end-to-end solutions to help clients realize their dreams of parenthood—including preconception genetic analysis for healthy conception, full-cycle in vitro fertilization (IVF) services, and fertility preservation services. Its genetic analysis service employs both 23-pair chromosome analysis and next-generation sequencing (NGS) technology, enabling precise screening for hereditary diseases and deleterious genetic variants—thereby providing robust support for healthy conception and birth.

Moreover, First Renhui Group has integrated several cutting-edge technologies: Platelet-Rich Plasma (PRP) therapy to promote ovarian rejuvenation in women aged 40 and above; NGS-based genetic sequencing to support healthy conception for individuals with familial hereditary disease histories; and fourth-generation IVF technology to restore fertility for patients experiencing diminished ovarian reserve or declining fertility. The adoption and application of these technologies have not only enhanced the quality and efficiency of clinical care but also significantly elevated patient satisfaction and trust.

Regarding corporate development, Mr. Siu announced a major milestone: First Renhui Group completed its initial public offering (IPO) on the Nasdaq Stock Market in April 2024. This strategic move will further accelerate the Group’s global business expansion and brand building, enabling it to deliver higher-quality, more comprehensive life science healthcare services to an even broader patient population.

As a successful entrepreneur, Mr. Siu brings rich startup experience and deep domain expertise. He holds a Bachelor’s and Master’s degree in Science from Stanford University and has founded and successfully taken multiple companies public in Hong Kong, Australia, and on the Nasdaq. His address at the WFA Brand Summit not only showcased First Renhui Group’s innovation capacity and growth potential in the life science field but also conveyed to the global community a firm commitment and unwavering determination to advance high-quality human development.

This article is a public-information summary published by WFA. It is intended for industry, media and the general public, and does not constitute medical or investment advice.